Cardiovascular System Marker Changes During A 12-Week Randomized Controlled Trial Of Oral Micronized Progesterone (Progesterone) For Effects On The Cardiovascular System.

Cardiovascular markers are summarized as mean (SD) at baseline and at the end of 12 weeks of randomized therapy to Progesterone (300 mg at bedtime) or identical Placebo in a hot flush and night sweat treatment trial [1]. The Framingham General Cardiovascular Profile is the percent (%) risk over 10 years for acute myocardial infarction, stroke, peripheral vascular disease or heart failure (General CVS Profile Score) [26]. Difference, 95% Confidence Interval (CI) and two-tailed P report the results of analysis of covariance. Results reaching statistical significance are in bold.